前立腺肥大症に伴う下部尿路症状に対するナフトピジルの長期投与の臨床的検討 - 国際前立腺症状スコア(IPSS)の変化, 閉塞症状, 膀胱刺激症状, 夜間頻尿および残尿量に関する検討 -

Abstract

前立腺肥大症候群患者67症例にナフトビジルを12ヵ月投与し, 国際前立腺症状スコア(IPSS)をもとに閉塞症状, 膀胱刺激症状, 夜間頻尿および尿残量の経時的変化から, 効果を検討した.IPSS の投与前合計点数の平均値は16.03±7.23であり, 12ヵ月後のスコアは10.00±5.00となり, 投与前と比較し有意に減少していた.投与前刺激症状スコアの平均値は6.12±4.34であり, 12ヵ月後には3.20±2.57となり, 投与前と比較し有意に減少していた.閉塞症状の経時変化では投与前は7.06±3.94であり, 12ヵ月後には5.33±3.22で有意に減少していた.夜間頻尿スコアの経時変化では投与前は2.85±1.43であり, 12ヵ月後には1.47±0.99で有意に減少していた.残尿量の変化では投与前は54.8±48.6mlであり, 12ヵ月後には35.1±30.5mlと有意に減少していた

Naftopidil was administered to 67 patients with benign prostatic hyperplasia (BPH) for 12 months. Changes in total/each International Prostate Symptom Score (IPSS) for irritative and obstructive symptoms, nocturia, and residual urine volume were compared before and after its administration. As a result, a significant decrease of score was found in total-IPSS, obstructive and irritative symptoms, which also showed a tendency to decrease at the end of the first month. Nocturia and residual urine volume also significantly decreased after its administration. Naftopidil is considered to be effective in the treatment of BPH, especially irritative symptoms including nocturia in treatments for BPH, because both irritative and obstructive symptoms (IPSS subjective endpoints) and residual urine volume (objective endpoint) were improved after its long-term administration.